Skip To Main Content

Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por
Cardiovascular management in patients with Fabry disease

Cardiovascular management in patients with Fabry disease

Management in Patients with Fabry Disease.

Cardiovascular management in patients with Fabry disease

Cardiovascular management in patients with Fabry disease

Management in Patients with Fabry Disease.

Cardiovascular management in patients with Fabry disease

Cardiovascular management in patients with Fabry disease

Management in Patients with Fabry Disease.

Cardiovascular management in patients with Fabry disease

Cardiovascular management in patients with Fabry disease

Management in Patients with Fabry Disease.

Cardiovascular management in patients with Fabry disease

Cardiovascular management in patients with Fabry disease

Management in Patients with Fabry Disease.

Kurzvortrag Beyfortus (Nirsevimab)

Kurzvortrag Beyfortus (Nirsevimab)

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024